Biomaterial Database

Pharmacokinetics of once-daily amikacin dosing in patients with cystic fibrosis. 1998

P M Beringer, and A A Vinks, and R W Jelliffe

UI	MeSH Term	Description	Entries
D003550	Cystic Fibrosis	An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION.	Mucoviscidosis,Cystic Fibrosis of Pancreas,Fibrocystic Disease of Pancreas,Pancreatic Cystic Fibrosis,Pulmonary Cystic Fibrosis,Cystic Fibrosis, Pancreatic,Cystic Fibrosis, Pulmonary,Fibrosis, Cystic,Pancreas Fibrocystic Disease,Pancreas Fibrocystic Diseases
D004334	Drug Administration Schedule	Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience.	Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000583	Amikacin	A broad-spectrum antibiotic derived from KANAMYCIN. It is reno- and oto-toxic like the other aminoglycoside antibiotics.	A.M.K,Amikacin Sulfate,Amikacina Medical,Amikacina Normon,Amikafur,Amikalem,Amikason's,Amikayect,Amikin,Amiklin,Amukin,BB-K 8,BB-K8,Biclin,Biklin,Gamikal,Kanbine,Oprad,Yectamid,BB K 8,BB K8,BBK 8,BBK8,Medical, Amikacina,Normon, Amikacina,Sulfate, Amikacin
D000900	Anti-Bacterial Agents	Substances that inhibit the growth or reproduction of BACTERIA.	Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial

Related Publications

P M Beringer, and A A Vinks, and R W Jelliffe

Pharmacokinetics of once and twice daily dosing of intravenous tobramycin in paediatric patients with cystic fibrosis.

August 2016, Journal of chemotherapy (Florence, Italy),

P M Beringer, and A A Vinks, and R W Jelliffe

Once-daily gentamicin dosing in pediatric patients without cystic fibrosis.

March 2010, Pharmacotherapy,

P M Beringer, and A A Vinks, and R W Jelliffe

Pharmacokinetics of once-daily amikacin in elderly patients.

January 1993, The Journal of antimicrobial chemotherapy,

P M Beringer, and A A Vinks, and R W Jelliffe

Pharmacokinetics of once-daily amikacin in pediatric patients.

February 1996, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases,

P M Beringer, and A A Vinks, and R W Jelliffe

Pharmacokinetics of once-daily versus thrice daily tobramycin in cystic fibrosis patients.

May 1996, The Journal of antimicrobial chemotherapy,

P M Beringer, and A A Vinks, and R W Jelliffe

Amikacin once daily: a new dosing regimen based on drug pharmacokinetics.

January 1990, Scandinavian journal of infectious diseases,

P M Beringer, and A A Vinks, and R W Jelliffe

Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis.

March 2017, The Cochrane database of systematic reviews,

P M Beringer, and A A Vinks, and R W Jelliffe

Once daily versus multiple daily dosing with intravenous aminoglycosides for cystic fibrosis.

January 2000, The Cochrane database of systematic reviews,